Effects of Su Jok Seed Therapy Application on Pain, Anxiety and Psychological Resilience in Patients Hospitalized in the Oncology Ward
Launched by MUŞ ALPARSLAN UNIVERSITY · Jul 29, 2024
Trial Information
Current as of August 20, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a therapy called su jok seed therapy to see how it might help patients with cancer who are experiencing pain, anxiety, or struggling emotionally. The goal is to find out if this therapy can lower pain levels, reduce anxiety, and improve how well patients cope with their illness. In the study, some patients will receive the su jok therapy eight times over four weeks, while another group will not receive any treatment during the same time.
To participate, individuals need to be over 18 years old, have been diagnosed with cancer, and have no issues communicating. Unfortunately, if a patient’s condition worsens or if they pass away during the study, they won’t be able to continue. This trial is still in the planning stages and has not started recruiting participants yet. If you or someone you know is interested in how this therapy could help with cancer-related symptoms, it may be worth discussing with a healthcare provider.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Being over 18 years old,
- • No communication problems,
- • Individuals diagnosed with cancer
- Exclusion Criteria:
- • Getting worse or dying during the research process
About Muş Alparslan University
Muş Alparslan University is a distinguished academic institution dedicated to advancing research and education in various fields, including health sciences. As a clinical trial sponsor, the university is committed to fostering innovative research initiatives that contribute to the understanding and treatment of medical conditions. By leveraging its academic resources, expertise, and collaborative partnerships, Muş Alparslan University aims to ensure the highest standards of scientific rigor and ethical conduct in clinical trials, ultimately enhancing patient care and contributing to the advancement of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported